PFS Improved With Talquetamab in Relapsed or Refractory Multiple Myeloma

THURSDAY, June 18, 2026-- Among patients with relapsed or refractory multiple myeloma who had previously received at least one line of therapy, talquetamab plus daratumumab and pomalidomide (Tal-DP) and talquetamab plus daratumumab (Tal-D) yield...